Medpage Today on MSN17h
Managing Primary Biliary Cholangitis Progression and SymptomsOnce clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver ...
2 There are currently no treatments approved for MASLD, formerly known as nonalcoholic fatty liver disease. Instead, ...
The Healthy on MSN2d
9 Fatty Liver Symptoms You Need to Watch Out ForNonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...
Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns.
Abbott's Freestyle Libre 2 and 3 are the first CGMs to receive FDA clearance for use during imaging tests like X-rays, CT ...
Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Research Progress on Multidisciplinary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Liver Cancer ...
Discover a new study that has examined the influence of clinical and histologic risk factors on long-term MASLD outcomes in ...
Obesity affects approximately one-third of adults in modern society and is a significant risk factor for diabetes, a threatening metabolic disease. It is also closely associated with several ectopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback